167 related articles for article (PubMed ID: 19192962)
1. mTOR inhibitors for hepatocellular cancer: a forward-moving target.
Treiber G
Expert Rev Anticancer Ther; 2009 Feb; 9(2):247-61. PubMed ID: 19192962
[TBL] [Abstract][Full Text] [Related]
2. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma.
Semela D; Piguet AC; Kolev M; Schmitter K; Hlushchuk R; Djonov V; Stoupis C; Dufour JF
J Hepatol; 2007 May; 46(5):840-8. PubMed ID: 17321636
[TBL] [Abstract][Full Text] [Related]
3. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
5. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
Zhu AX
Expert Opin Investig Drugs; 2010 May; 19(5):663-72. PubMed ID: 20367287
[TBL] [Abstract][Full Text] [Related]
6. The impact of mTOR inhibitors on the development of malignancy.
Geissler EK
Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
[TBL] [Abstract][Full Text] [Related]
7. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis.
Seeliger H; Guba M; Kleespies A; Jauch KW; Bruns CJ
Cancer Metastasis Rev; 2007 Dec; 26(3-4):611-21. PubMed ID: 17713840
[TBL] [Abstract][Full Text] [Related]
8. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
9. Novel inhibitors in development for hepatocellular carcinoma.
Wörns MA; Galle PR
Expert Opin Investig Drugs; 2010 May; 19(5):615-29. PubMed ID: 20374038
[TBL] [Abstract][Full Text] [Related]
10. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation.
Sieghart W; Fuereder T; Schmid K; Cejka D; Werzowa J; Wrba F; Wang X; Gruber D; Rasoul-Rockenschaub S; Peck-Radosavljevic M; Wacheck V
Transplantation; 2007 Feb; 83(4):425-32. PubMed ID: 17318075
[TBL] [Abstract][Full Text] [Related]
11. The role of mTOR inhibitors in the management of posttransplant malignancy.
Monaco AP
Transplantation; 2009 Jan; 87(2):157-63. PubMed ID: 19155967
[TBL] [Abstract][Full Text] [Related]
12. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A; Figlin RA
Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?
Duvoux C; Toso C
Transplant Rev (Orlando); 2015 Jul; 29(3):168-74. PubMed ID: 26071984
[TBL] [Abstract][Full Text] [Related]
14. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
Wu XZ
Neoplasma; 2008; 55(6):472-81. PubMed ID: 18999874
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapy for hepatocellular carcinoma.
Thomas MB
Cancer J; 2008; 14(2):123-7. PubMed ID: 18391618
[TBL] [Abstract][Full Text] [Related]
16. Growth factors as therapeutic targets in HCC.
Furuse J
Crit Rev Oncol Hematol; 2008 Jul; 67(1):8-15. PubMed ID: 18434184
[TBL] [Abstract][Full Text] [Related]
17. Targeting mTOR in renal cell carcinoma.
Hudes GR
Cancer; 2009 May; 115(10 Suppl):2313-20. PubMed ID: 19402072
[TBL] [Abstract][Full Text] [Related]
18. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
Bertoni E; Salvadori M
J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma.
Ribatti D; Vacca A; Nico B; Sansonno D; Dammacco F
Cancer Treat Rev; 2006 Oct; 32(6):437-44. PubMed ID: 16870349
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]